妒海

IPO周报｜本周4只新股申购国内轴承制造龙头来了_我的网站

财经郎眼

A |

Francesco Faiola
Editor's Note:
Ahead of the opening of the 2026 World AI Conference and High-Level Meeting on Global AI Governance, Chinese AI start-up Moonshot AI released its Kimi K3 large language model. As the world's largest open-source model by parameter count to date, this launch marks a significant step forward in the development of China's artificial intelligence models.
From the C919 airliner soaring into the skies to Unitree's humanoid robots stealing the show; from DeepSeek pushing the AI frontier to Moonshot AI's landmark unveiling of Kimi K3 - China's wave of homegrown innovations has dominated global headlines in recent years, delivering a steady stream of breakthroughs.
At a meeting in Beijing that brought together the national science and technology award conference, the general assemblies of the members of the Chinese Academy of Sciences (CAS) and the Chinese Academy of Engineering (CAE), and the 11th national congress of the China Association for Science and Technology in July, Chinese President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, stressed that the 15th Five-Year Plan period (2026-2030) is a critical phase for tackling tough challenges in building up the country's strength in science and technology.
"We must seize the historic opportunity, rise to the challenges of the times, accelerate efforts to achieve high-level self-reliance and strength in science and technology, and make steady progress toward the 2035 goal of becoming a leading country in science and technology," he said.
In the article "Strive for Greater Strength and Self-Reliance in Science and Technology" included in the fourth volume of Xi Jinping: The Governance of China, Xi pointed out, "Through years of endeavor, our country's overall strength in science and technology has improved substantially. We therefore have a solid foundation, and are fully confident in our ability to seize the opportunities offered by the new revolution in science, technology and industry to achieve greater results." The article also mentioned that "We should participate to the full in global science and technology governance, contribute Chinese wisdom, and shape a philosophy of technology for good purposes, so that science and technology better serve human wellbeing, and enable China's science and technology industry to contribute more to building a global community of shared future."
In the 27th installment of the special series "Decoding the Book Xi Jinping: The Governance of China," the Global Times, along with the People's Daily Overseas Edition, continues to invite Chinese and foreign scholars, translators of Xi's works, practitioners with firsthand experience, and international readers to focus on the theme of striving for greater strength and self-reliance in science and technology. Together, they share views on China's tech growth, governance principles, and global cooperation in science and technology.
In the 27th article of the "Readers' Reflections" column, Global Times (GT) talked to Francesco Faiola (Faiola), an Italian professor at the Research Center for Eco-Environmental Sciences with Chinese Academy of Sciences and recipient of the Chinese Government Friendship Award.
GT: Chinese President Xi Jinping delivered a keynote speech at the opening ceremony of the 2026 World AI Conference and High-Level Meeting on Global AI Governance on July 17. He said that as a responsible major country, China is always committed to providing international public goods relating to AI. In the article "Boost Basic Research and Achieve Greater Strength and Self-Reliance in Science and Technology" included in the fifth volume of Xi Jinping: The Governance of China, Xi said, "It is important that we adopt a more open-minded approach to international exchange and cooperation in research to create an open, globally competitive innovation ecosystem." Amid the current complex global landscape, China remains firmly committed to keeping its doors open to international scientific collaboration. In your view, where does China's confidence in this commitment come from?
Faiola: I think China's confidence in staying open comes from a deep shift in mindset. The Chinese people, especially the scientific community, now really believe they are not inferior to Westerners. For a long time, even many people here thought top science had to happen at a Western address. When I first came, I believed that too. The US and Europe seemed like the only serious places for breakthroughs. Now that idea is changing, and moving toward China, because the evidence of leadership is everywhere: stem cell standards, artificial intelligence (AI) efficiency, green manufacturing. It's undeniable. China knows it has everything needed to attract and keep international talent. It's no longer a developing country playing catch up. It's a place that's helping set the global agenda.
That self-assurance is the bedrock of openness. When you truly believe you have unique strengths, like a huge organoid screening capability or a community of scientists who think deeply, you don't fear open doors. You want colleagues from everywhere to walk through so the science moves faster. My own lab works with European centers as equals. That parity is real. But we also know not everyone abroad gets this transformation yet. A lot of people still imagine Chinese science as just following others. That's exactly why China is pushing openness harder: funding lines for foreign principal investigators, open innovation hubs in Beijing, active participation in setting international standards. These aren't defensive moves. They're proof of a country confident enough to invite the world in, show what it can do, and create knowledge together.
On a deeper level, the confidence is also just rational. The big challenges - environmental problem, pandemic preparedness and precision medicine - are global. If China closed itself off, the data and validation its own regulators need would get weaker. So, the open door isn't charity. It's the smart recognition that scientific greatness today gets multiplied when you share it.
GT: In the article "Strive for Greater Strength and Self-Reliance in Science and Technology" included in the fourth volume of Xi Jinping: The Governance of China, Xi pointed out, "Through years of endeavor, our country's overall strength in science and technology has improved substantially. We therefore have a solid foundation, and are fully confident in our ability to seize the opportunities offered by the new revolution in science, technology and industry to achieve greater results." From the domestically built large passenger jet to DeepSeek, Unitree Robotics, and Moonshot AI's Kimi K3, China's innovation achievements have been making headlines. How do you assess China's achievements in sci-tech innovation in recent years?

Faiola: I measure China's innovation success in a very personal way. My parents are old, living in a small Italian town. They don't speak English. They don't understand molecular biology. They can't read a scientific paper. But over the past few years, they've called me up more than once, excited, telling me about a Chinese airplane or a humanoid robot or some AI breakthrough they saw on Italy's main TV news or in the newspapers.
That tells me something deep. These aren't niche stories for tech insiders. They are real global news, landing in the living rooms of retirees who barely use a smartphone. I'm not bragging to them about China's progress. They are telling me. When achievements get that far into everyday European life, it's a sign China is doing something the world finds worth talking about.
The C919 plane, DeepSeek, Unitree Robotics - these aren't one-off hits. They prove China can now conceive, design, and build complex, original systems on its own, whether it's an airliner, an advanced AI model, or an agile robot. That takes deep integration across different fields, aerodynamics, materials, real time control, and AI.
DeepSeek's whole philosophy, doing more with less, is exactly how we created affordable organoid screening tools. And the quiet shift from rule taker to rule maker in chemical safety standards, that mirrors the C919's ambition to compete globally on certification. All this shows China is blending manufacturing, digital smarts, and biology into one force. But my real proof is what I hear from my students. They don't just apply discoveries from papers anymore. They question the assumptions behind them. That intellectual confidence, and the fact it echoes all the way back to a small Italian town, is why I'm sure China will fully seize this moment.
GT: President Xi said that AI development should not be a solo performance by a single country, but a symphony of international cooperation. Having conducted research in China for many years, you are not only a witness but also a driving force behind China-Europe scientific exchanges. Looking ahead, how can both sides deepen complementary advantages and achieve mutually beneficial empowerment to jointly address global challenges such as climate change and health? Over the next five years, which specific sectors should China-Europe science and technology collaboration prioritize?
Faiola: I grew up in Italy and now I lead a lab in Beijing while working with colleagues all over Europe. So, China-Europe teamwork isn't some abstract idea to me. It's how my week actually looks. The old cliché, European basic research plus Chinese scale and speed, is already outdated. Both sides now generate novel insights. The relationship has to become genuine two-way cocreation.
I see three practical things that would deepen it. First, we need truly joint funding: one grant, one integrated team, maybe a Max Planck group and a Chinese Academy of Sciences group, with a single scientific plan and students who genuinely rotate between the labs. Second, we need to harmonize regulations and ethics for organoid technologies. Europe has advanced thinking on governance. China has manufacturing scale and the drive to get things into clinics. If we co-develop shared quality and ethical standards for organoid testing, we basically set the global benchmark. A liver organoid made in Europe could then be used directly for a toxicity screen in China without repeating all the validation. Third, we need deliberate talent circulation, not a zero-sum competition. Joint PhD programs where a student naturally moves between continents.
The science doesn't care about borders. If we build the shared tools now, China and Europe can show the world a model where shared knowledge beats division.
GT: Recently, some Western media and think tanks are peddling "China Shock 2.0," claiming that China is achieving fast development in high-tech sectors such as renewable energy and AI and relies on foreign markets to absorb its overcapacity, thus reducing the market share of developed countries and sending more serious shock waves to the global economy compared with the era of traditional manufacture industry. What's your comment on this? In your view, does this represent a new pretext for Western protectionism, or is it an unavoidable external misunderstanding amid China's industrial upgrading?

Faiola: I'm a bench scientist, not a political analyst. I stick to what I can see and measure in my own work. So, I'm not going to guess what the media or think tanks intend. I'll just tell you what the facts show me, and from my lab, the "China Shock 2.0" story just doesn't match up.
In my field of stem cell toxicology, the world is desperate for human relevant safety tests to replace animal testing. Tens of thousands of chemicals still don't have proper hazard data. When Chinese labs turn out high throughput organoid platforms at a fraction of the old cost, that's not dumping "overcapacity" into a full market. It's filling a huge shortage. A researcher in Brazil or Kenya suddenly gets access to a toxicity screen that never existed for them before. Demand is skyrocketing, not standing still. Meeting that demand is a service, not a shock.
With AI, it's the same pattern. DeepSeek's efficiency makes it cheaper and easier for biomedical researchers around the world to use these tools. It's helping create new markets, not stealing a fixed pie. Sure, any big shift causes some dislocation. The answer to that is domestic support and transition policies, not blocking technologies that help solve planetary problems.
。　　本周新股申购迎来4家细分领域头部公司。　　澎湃新闻根据Wind及公开信息梳理统计，本周（8月24日至8月28日）有4只新股安排申购，分别为广东华汇智能装备股份有限公司（下称“华汇智能”，920289）、洛阳轴承集团股份有限公司（下称“洛轴股份”，301699）、天博智能科技（山东）股份有限公司（下称“天博智能”，603448）、中电科思仪科技股份有限公司（下称“电科思仪”，301689）。　　其中，洛轴股份主营轴承及相关零部件的研发、生产和销售，是中国轴承行业规模最大的综合性轴承制造企业之一。

　　一、本周新股申购　　从时间表看，华汇智能（920289）在本周一（8月24日）申购，洛轴股份（301699）、天博智能（603448）均在本周三（8月26日）申购，电科思仪（301689）则在本周五（8月28日）申购。

　　据开源证券研报，华汇智能是一家专业从事高端智能装备及其关键部件的研发、设计、生产和销售的高新技术企业。

B | 公司纳米砂磨机产品已取得欧洲CE认证，具备欧洲市场的拓展能力。公司与湖南裕能、万润新能、贝特瑞、比亚迪、中海油等知名锂电池材料企业和国内大型央企建立良好的合作关系，在锂电池材料研磨系统领域具有较高的品牌知名度和较强的竞争力。

C | 　　2023年至2025年，公司总营收持续增长，分别为3.00亿元、4.27亿元以及6.16亿元。2023年至2025年，公司归母净利润持续增长，分别为4643.32万元、6262.32万元以及8042.35万元。同期公司毛利率分别为32.74%、31.67%以及27.92%，净利率分别为15.30%、14.68%以及12.32%。　　Wind资料显示，洛轴股份主营轴承及相关零部件的研发、生产和销售，是中国轴承行业规模最大的综合性轴承制造企业之一。公司深耕轴承行业多年，科技创新能力突出，拥有轴承行业唯一国家重点实验室，在高端轴承领域研发与布局处于国内领先地位。　　公司前身为始建于1954年的洛阳轴承厂，是国家“一五”计划期间156个重点建设项目之一。公司产品研发突出国家战略需求，承担多项国家科技攻关任务，是国内首批开展高速动车组轴承(或高铁轴承)研究的企业，承担了C919、C929国产客机发动机主轴轴承与传动系统附件轴承的研制配套任务。　　同时，公司是风力发电、轨道交通、航空航天及军工、新能源汽车等下游领域主要轴承配套供应商，多项产品市场占有率排名行业前三，主要客户覆盖国铁集团、中国中车集团、中国船舶、比亚迪、运达股份、远景能源、东方电气、上海电气、三一集团、金风科技等主机行业龙头企业，具备良好客户基础及广泛市场影响力。

D | 　　Wind资料显示，天博智能是行业内知名的汽车热管理系统零部件制造商，并拓展了汽车声学部件等业务，公司主营产品主要应用于汽车领域。　　公司客户已覆盖国内大部分主机厂，拥有广泛且优质的客户资源和较强的品牌影响力，2024年中国汽车销量前十位的车企集团均是公司的当期客户。在储能、AI数据中心服务器等非汽车领域，公司热管理产品近年来亦有所拓展。　　Wind资料显示，电科思仪是一家专业从事电子测量仪器研发、制造和销售的高科技企业，拥有国内规模最大的专业研发队伍，是国内综合实力最强、收入规模最大的电子测量仪器研发制造企业。　　公司是国内电子测量仪器产品门类最全、频谱覆盖范围最宽的企业，主要产品包括整机、测试系统、整部件等，相关产品性能国内领先、国际先进。公司收入主要来源于上述产品的销售。　　二、本周新股上市　　从时间表看，本周暂有1只新股上市，高凯技术（688835）将在本周二上市。

E | 　　Wind资料显示，高凯技术专业从事精密流体控制领域中关键控制部件及相关设备的研发、生产与销售。

F | 目前公司产品以流量控制系列、点胶封装系列和精密涂胶系列为核心，并延伸至更多种类的精密流体控制部件及相关设备，广泛应用于半导体、消费电子、汽车电子和新能源等智能制造领域。　　在行业公认具有较高技术门槛的半导体设备领域，公司是目前国内极少数能够量产供货，且应用于先进工艺制程节点的半导体设备关键流体控制部件供应商。主营产品已经成功通过国内知名厂商验证，并实现了稳定量产供应，部分产品批量应用于7nm及以下逻辑芯片等先进制程前道工艺设备。　　公司自2013年成立以来，主营业务逐步向新能源精密涂胶领域、半导体设备流体控制领域拓展，形成了流量控制系列、点胶封装系列和精密涂胶系列三大业务板块，可以为不同领域客户提供精密流体控制部件及相关设备的综合一体化解决方案，多款产品打破了国际厂商在精密流体控制领域对国内市场的长期垄断局面。

G | 　　上周，共有6只新股上市。　　8月21日，信胜科技（920093）在北交所挂牌上市，发行价为14.35元/股，截至上市首日收盘，该股报23.19元/股，涨幅为61.6%。以收盘价计算，投资者中一签浮盈为884元。　　8月20日，C绿控（301655）在创业板挂牌上市，发行价为8.5元/股，截至上市首日收盘，该股报32.49元/股，涨幅为282.24%。以收盘价计算，投资者中一签浮盈为1.20万元。　　8月19日，C宇树-W（688836）在科创板挂牌上市，发行价为150.8元/股，截至上市首日收盘，该股报845元/股，涨幅为460.34%。以收盘价计算，投资者中一签浮盈为34.71万元。　　8月19日，双英集团（920059）在北交所挂牌上市，发行价为11.13元/股，截至上市首日收盘，该股报24.75元/股，涨幅为122.37%。以收盘价计算，投资者中一签浮盈为1362元。　　8月18日，C频准（688826）在科创板挂牌上市，发行价为186.88元/股，截至上市首日收盘，该股报1152元/股，涨幅为516.44%。以收盘价计算，投资者中一签浮盈为48.26万元。

H | 　　8月17日，恒兴股份（920107）在北交所挂牌上市，发行价为16.02元/股，截至上市首日收盘，该股报30.05元/股，涨幅为87.58%。以收盘价计算，投资者中一签浮盈为1403元。　　三、上周IPO过会　　发审委审核，上周上交所、深交所、北交所均召开了新一期上市审核委员会审议会议。　　其中，拟在科创板上市的广东钶锐锶数控技术股份有限公司（下称“钶锐锶”），拟在创业板上市的东莞优邦材料科技股份有限公司（下称“优邦科技”），以及拟在北交所上市的东莞市元立光电股份有限公司（下称“元立光电”）、无锡鑫巨宏智能科技股份有限公司（下称“鑫巨宏”）、浙江正导技术股份有限公司（下称“正导技术”）等，均成功过会。　　本周，北交所将继续开审。　　8月28日，北交所将审议江苏苏讯新材料科技股份有限公司（下称“苏讯新材”）的首发事项。公司是一家专注于金属包装材料研发、生产及销售的高新技术企业。公司产品线涵盖了马口铁包装材料(镀铬薄板、镀锡薄板等)、食品级不锈钢薄板、钢塑复合薄板(热覆膜铁、光纤光缆用钢塑复合带)等多种类型。　　四、港股最新动态　　港股方面，Wind数据显示，本周（8月24日至8月28日）暂无新股申购安排。

I | 君正股份（03223.HK）将在本周二上市。　　上周，湖南裕能新能源电池材料股份有限公司首次递交港股招股书。

J | 　　君乐宝乳业集团股份有限公司、博纳西亚(杭州)医药科技股份有限公司、本末动力(北京)科技股份有限公司等更新了港股招股书。　　彤程新材料集团股份有限公司、钱大妈国际控股有限公司、益方生物科技(上海)股份有限公司等港股申请失效。　　深圳麦科田生物医疗技术股份有限公司等聆讯通过。　　五、投融资大事记　　1、8月21日，清雁科技宣布于近日完成数亿元A轮融资。本轮融资由君联资本领投，苏创投、宁波亿时跟投。　　2、8月21日，原子矩阵宣布于近日完成数亿元人民币A+轮融资。

K | 本轮融资由云锋基金、三七互娱、普华资本、财通资本、上海半导体产投、唐兴资本、博睿资本、合创资本、海邦投资等多家机构联合投资，老股东民银国际持续加注。　　3、8月20日，中科第五纪宣布于近日连续完成超10亿元A1、A2轮融资。A1轮由锡高投、中银AIC基金、三锋投资联合投资。A2轮由芯能创投、中银AIC基金、中山创投、鸿瑞达投资、博彦科技、金创投（浙江省新能源汽车子基金）联合投资。　　4、8月20日，工研拓芯宣布于近日完成亿元A轮融资。本轮融资由策源资本、洛阳科创集团、华天电子集团、农银国际联合投资。　　5、8月20日，时安生物宣布完成近4亿元人民币A轮系列融资，涵盖Pre-A轮、A轮及 A+轮。